Bile acids in regulation of inflammation and immunity: Friend or foe?

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages S25-S31

  Zhu, Ci ^a   Fuchs, Claudia D ^a   Halilbasic, Emina ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adaptive and innate immunity; Bile acid signalling; Cholangiopathies; G protein coupled receptors; Hepatitis; Nuclear hormone receptors

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; PLACEBO; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT; AUTACOID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN; LIGAND;

ADAPTIVE IMMUNITY; ARTICLE; ASTHMA; BILE ACID SYNTHESIS; BILE DUCT LIGATION; BONE MARROW DERIVED DENDRITIC CELL; CHOLESTASIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; KUPFFER CELL; LIVER DISEASE; LIVER PROTECTION; MONOCYTE; MYELOID DENDRITIC CELL; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHAGOCYTOSIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; SCHISTOSOMIASIS MANSONI; T LYMPHOCYTE; AGONISTS; ANIMAL; BILE DUCT; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; BILE DUCTS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; LIGANDS; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84984832899     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. BEUERS U, BOYER JL: Bile: A historical review of studies on its form and function. In: KIRSNER JB (Ed.): Gastroenterology in the 20th century. New York, Lea & Febiger, 1994: 267-88.
2. TRAUNER M, FICKERT P, HALILBASIC E, MOUSTAFA T: Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008; 158: 542-48.
3. WOOLBRIGHT BL, JAESCHKE H: Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol 2012; 18: 4985-93.
4. AMARAL JD, VIANA RJ, RAMALHO RM, STEER CJ, RODRIGUES CM: Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721-34.
5. BHOGAL HK, SANYAL AJ: The molecular pathogenesis of cholestasis in sepsis. Front Biosci 2013; 5: 87-96.
6. TRAUNER M, MEIER PJ, BOYER JL: Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.
7. TRAUNER M, GRAZIADEI IW: Review article: mechanisms of action and therapeutic applications. Aliment Pharmacol Ther 1999; 13: 979-95.
8. SMIT JJ, SCHINKEL AH, OUDE ELFERINK RP: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 5: 451-62.
9. SCHAAP FG, TRAUNER M, JANSEN PL: Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
10. TRAUNER M, HALILBASIC E: Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125. e1-12.
11. BEUERS U, TRAUNER M, JANSEN P, POUPON R: New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: S25-37.
12. BAGHDASARYAN A, CLAUDEL T, GUMHOLD J et al.: Dual Farnesoid X Receptor/TGR5 Agonist INT.767 reduces liver injury in the Mdr22/2 (Abcb42/2) mouse cholangiopathy model by promoting biliary HCO3- output. Hepatology 2011; 54: 1303-12.
13. SCHOTE AB, TURNER JD, SCHILTZ J, MULLER CP: Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007; 44: 1436-45.
14. WANG YD, CHEN WD, WANG M, YU D, FORMAN BM, HUANG W: Farnesoid X receptor antagonizes Nuclear Factor kappa B in hepatic inflammatory response. Hepatology 2008; 48: 1632-1643.
15. POLS TW, NOMURA M, HARACH T et al.: TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14: 747-57.
16. WANG YD, CHEN WD, YU D, FORMAN BM, HUANG W: The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing Nuclear Factor Kappa Light- Chain Enhancer of Activated B Cells (NFkB) in mice. Hepatology 2011; 54: 1421-32.
17. ZHANG H, LIU Y, BIAN Z et al.: The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. J Autoimmun 2014; 53: 55-56.
18. LEWIS ND, PATNAUDE LA, PELLETIER J et al.: A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces Experimental Autoimmune Encephalitis (EAE) in vivo. Plos One 2014; 9 e100883: 1-11.
19. HO PP, STEINMAN L: Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2016; 113: 1600-5.
20. JONES H, ALPINI G, FRANCIS H: Bile acid signaling and biliary functions. Acta Pharmaceutica Sinica B 2015; 5: 123-28.
21. TRAUNER M, HALILBASIC E: Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 40: 1120-1125.e1-12.
22. HALILBASIC E, CLAUDEL T, TRAUNER M: Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013; 58: 155-68.
23. LI S, ZHAO Y, HE X et al.: Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 2002; 277: 26912-20.
24. QIAO L, STUDER E, LEACH K et al.: Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogenactivated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 2001; 12: 2629-45.
25. REINEHR R, BECKER S, EBERLE A, GRETHER- BECK S, HäUSSINGER D: Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem 2005; 280: 27179-94.
26. JEAN-LOUIS S, AKARE S, ALI MA, MASH EA JR, MEUILLET E, MARTINEZ JD: Deoxycholic acid induces intracellular signaling through membrane perturbations. J Biol Chem 2006; 281: 14948-60.
27. ADACHI T, KAMINAGA T, YASUDA H, KAMIYA T, HARA H: The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury. J Clin Biochem Nutr 2014; 54: 129-35.
28. GUJRAL JS, LIU J, FARHOOD A, HINSON JA, JAESCHKE H: Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 2004; 286: G499-G507.
29. OHTSUKA M, MIYAZAKI M, KUBOSAWA H et al.: Role of neutrophils in sinusoidal endothelial cell injury after extensive hepatectomy in cholestatic rats. J Gastroenterol Hepatol 2000; 15: 880-6.
30. GUJRAL JS, FARHOOD A, BAJT ML, JAESCHKE H: Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct- ligated mice. Hepatology 2003; 38: 355-63.
31. PUNTIS MCA, JIANG WG, HALLET MB: Neutrophil oxidative response and its relationship to clinical outcomes in jaundiced patients. HPB Surg 1992; 5: 204.
32. ALLEN K, JAESCHKE H, COPPLE BL: Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011; 178: 175-86.
33. DAHM LJ, ROTH RA: Differential effects of lithocholate on rat neutrophil activation. J Leuk Biol 1990; 47: 551-60.
34. SUNG JJY, GO MYY: Reversible Kupffer cell suppression in biliary obstruction is caused by hydrophobic bile acids. J Hepatol 1999; 30: 413-18.
35. JIANG WG, PUNTIS MC: Immune dysfunction in patients with obstructive jaundice, mediators and implications for treatments. HPB Surg 1997; 10: 129-42.
36. KERFOOT SM, D'MELLO C, NGUYEN H et al.: TNF-alpha-secreting monocytes are recruited into the brain of cholestatic mice. Hepatology 2006; 43: 154-62.
37. PILLARISETTY VG, SHAH AB, MILLER G, BLEIER JI, DEMATTEO RP: Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 2004; 15: 1009-17.
38. BLEIER JI, KATZ SC, CHAUDHRY UI et al.: Biliary obstruction selectively expands and activates liver myeloid dendritic cells. J Immunol 2006; 176: 7189-95.
39. CONNOLLY MK, BEDROSIAN AS, MALLENST CLAIR J: In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119: 3213-25.
40. LUKACS-KORNEK V, SCHUPPAN D: Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol 2013; 59: 1124-6.
41. RAHMAN AH, ALOMAN C: Dendritic cells and liver fibrosis. Biochim Biophys Acta 2013; 7: 998-04.
42. CARAMBIA A, FREUND B, SCHWINGE D: TGF-ß-dependent induction of CD4+CD25+ Foxp3+ Tregs by liver sinusoidal endothelial cells. J Hepatol 2014; 61: 594-99.
43. LICATA LA, NGUYEN CT, BURGA RA: Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils. J Leukoc Biol 2013; 94: 813-23.
44. O'BRIEN KM, ALLEN KM, ROCKWELL CE, TOWERY K, LUYENDYK JP, COPPLE BL: IL-17A synergistically enhances bile acidinduced inflammation during obstructive cholestasis. Am J Pathol 2013; 183: 1498-07.
45. POLS TW, NORIEGA LG, NOMURA M, AUWERX J, SCHOONJANS K: The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011; 54: 1263-72.
46. WANG YD, CHEN WD, WANG M, YU D, FORMAN BM, HUANG W: Farnesoid X receptor antagonizes nuclear factor kappa B in hepatic inflammatory response. Hepatology 2008; 48: 1632-43.
47. MENCARELLI A, RENGA B, MIGLIORATI M et al.: The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 2009; 183: 6657-66.
48. VERBEKE L, FARRE R, VERBINNEN B et al.: The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 2015; 185: 409-19.
49. KIDA T, TSUBOSAKA Y, HORI M, OZAKI H, MURATA T: Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 1663-9.
50. McMAHAN RH, WANG XX, CHENG LL et al.: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288: 11761-70.
51. ICHIKAWA R, TAKAYAMA T, YONENO K et al.: Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 2012; 136: 153-62.
52. KEITEL V, DONNER M, WINANDY S, KUBITZ R, HäUSSINGER D: Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372: 78-84.
53. HIRSCHFIELD GM, MASON A, LUKETIC V et al.: Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-61.
54. NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ et al.: NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 14: 956-65.
55. WANG YD, CHEN WD, LI C et al.: Farnesoid X Receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol 2015: 29: 322-31.
56. BEUERS U: Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-28.
57. DILGER K, HOHENESTER S, WINKLERBUDENHOFER U: Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 2012; 57: 133-40.
58. MITSUYOSHI H, NAKASHIMA T, SUMIDA Y et al.: Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263: 537-42.
59. LJUBUNCIC P, TANNE Z, BOMZON A: Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000; 45: 1921-28.
60. BOTLA R, SPIVEY JR, AGUILAR H, BRONK SF, GORES GJ: Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995; 272: 930-38.
61. RODRIGUES CM, FAN G, MA X, KREN BT, STEER CJ: A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-99.
62. BEUERS U, BILZER M, CHITTATTU A et al.: Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 1206-16.
63. BEUERS U, HOHENESTER S, de BUY WENNIGER LM, KREMER AE, JANSEN PLM, OUDE ELFERINK RP: The biliary HCO3 - umbrella. Hepatology 2010; 52: 1489-96.
64. HOHENESTER S, WENNIGER LM, PAULUSMA CC et al.: A biliary HCO3 - umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012; 55: 173-83.
65. YOSHIKAWA M, TSUJII T, MATSUMURA K et al.: Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.
66. OMATA M, YOSHIDA H, TOYOTA J et al.: A largescale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007; 56:; 1747-53.
67. YAMAZAKI K, GLEICH GJ, KITA H: Bile acids induce eosinophil degranulation by two different mechanisms. Hepatology 2001; 33: 582-90.
68. YAMAZAKI K, SUZUKI K, NAKAMURA A et al.: Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999; 30: 71-78.
69. MIURA T, OUCHIDA R, YOSHIKAWA N et al.: Functional modulation of the glucocorticoid receptor and suppression of NF-kappa B dependent transcription by ursodeoxycholic acid. J Biol Chem 2001; 276: 47371-78.
70. WILLART MA, van NIMWEGEN M, GREFHORST A et al.: Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy 2012; 67: 1501-10.
71. HALILBASIC E, FIOROTTO R, FICKERT P et al.: Side chain structure determines unique physiologic and therapeutic properties of norUrsodeoxycholic acid in Mdr2-/-Mice. Hepatology 2009; 49: 1972-81.
72. TRAUNER M, HALILBASIC E, CLAUDEL T et al.: Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis 2015; 33: 433-9.
73. FICKERT P, POLLHEIMER MJ, SILBERT D et al.: Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013; 58: 1201-08.
74. MOUSTAFA T, FICKERT P, MAGNES C et al.: Alterationsin lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012; 142: 140-151 e12.
75. MOUSTAFA T, HALILBASIC E, FICKERT P et al.: Side chain modified bile acids modulate endoplasmic reticulum stress in Mdr2 -/- mice in vivo and bile duct epithelial cells in vitro. J Hepatol 2008; 48: S54-S55.
76. TANG Y, FICKERT P, TRAUNER M, MARCUS NY, BLOMENKAMP KS, TECKMAN J: Autophagy Induced by Exogenous bile acids is therapeutic in a model of alpha-1-AT deficiency liver disease. Am J Physiol Gastrointest Liver Physiol 2016; 311 :G156-65.
77. HALILBASIC E, CLAUDEL T, BACHHOFNER N, KAPUSTA C, TRAUNER M: Norursodeoxycholic acid modulates LPS-induced inflammatory response by interfering with NF-ΚB signalling pathway. J Hepatol 2012; 56: S140.
78. SOMBETZKI M, FUCHS CD, FICKERT P et al.: 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 2015; 62: 871-78.